Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial - Wikidata - thesis-toulmin - TriplyDB

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

http://www.wikidata.org/entity/Q28301659

about

Interferon for people with lamivudine-resistant chronic hepatitis B virus infection Adefovir dipivoxil for adults with lamivudine-resistant chronic hepatitis B virus infection Bicyclol for chronic hepatitis B Antiviral drugs for viruses other than human immunodeficiency virus Interferon and lamivudine vs. interferon for hepatitis B e antigen-positive hepatitis B treatment: meta-analysis of randomized controlled trials Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog Therapy Management of HBV and HBV/HDV-Associated Liver Cirrhosis KASL clinical practice guidelines: management of chronic hepatitis B Effect of Telbivudine Versus Other Nucleos(t)ide Analogs on HBeAg Seroconversion and Other Outcomes in Patients with Chronic Hepatitis B: A Network Meta-Analysis Hepatitis B virus therapy: What's the future holding for us?Genomic Diversity of Hepatitis B Virus Infection Associated With Fulminant Hepatitis B Development Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck Antiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferon Current and future directions for treating hepatitis B virus infection Systematic review with meta-analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection?Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines Antiviral therapy for chronic hepatitis B in China Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments Direct acting antivirals for the treatment of chronic viral hepatitis Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B Treatment strategies according to genotype for chronic hepatitis B in children The Role of Interferon Lambda 3 Genetic Polymorphisms in Response to Interferon Therapy in Chronic Hepatitis B Patients: An Updated Meta-Analysis Current and future antiviral drug therapies of hepatitis B chronic infection Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Advancing patient care: integrating new data.Management of chronic hepatitis B virus infection: current perspectives for the nurse practitioner.The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation.Severe fever with thrombocytopenia syndrome virus inhibits exogenous Type I IFN signaling pathway through its NSs invitro Global control of hepatitis B virus: does treatment-induced antigenic change affect immunization?Alpha-interferon treatment in hepatitis B Hepatitis B virus genetic mutations and evolution in liver diseases.RNA Interference inhibits hepatitis B virus of different genotypes in vitro and in vivo Chronic hepatitis B: Advances in treatment.Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks Molecular identification of hepatitis B virus genotypes/subgenotypes: revised classification hurdles and updated resolutions.Antiviral therapy and resistance with hepatitis B virus infection.Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B.Inhibition of hepatitis B viral entry by nucleic acid polymers in HepaRG cells and primary human hepatocytes Pegylated IFN-alpha 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B.Molecular analysis of hepatitis B virus isolates in Mexico: predominant circulation of hepatitis B virus genotype H.

P2860

Q24185973-B72F359C-C05A-4016-9D8C-0C94A59A8BE0 Q24187530-276FFAA0-85AE-4701-B2A4-6A9ACBFB1096 Q24243889-7BF36D22-F86B-4A6A-AD41-5052FD94BBEC Q24635330-717504D0-2DF6-49C7-A553-C0D3C293C451 Q24683341-3626196C-4B49-405D-9374-E71D46661D66 Q26740161-AE41D0AA-87F2-4145-B71F-2F0D62FAB72D Q26740323-9F71CCDA-DC7D-4AF6-A84D-114A34A7A770 Q26752475-84C62FB8-24FC-4887-BFF8-9A2A08275EFC Q26766014-5262F241-BD61-4D2C-87A6-B10B9C4D4177 Q26774198-91A175F9-95AD-4ACD-9317-76590FBB0F10 Q26796488-81415D0D-0A38-42A8-BEFA-E6597229ADF6 Q26828598-7838EA91-15CD-4709-8A85-3A71EDC2E76B Q26830435-BE28F1A3-213C-408E-9EE0-7CB16580D28E Q26851240-4C017961-4CEC-40E1-B8B9-E26CB82F33CB Q26865747-6D807078-2195-441B-AE51-56104F617AFA Q27000080-617C89D3-5EB9-44B5-BCCA-7E8F5A1EFCE4 Q27006557-5A259EC0-3CE0-468A-AA4D-9CF2AC00E684 Q27008984-1032D3B8-9B61-4981-8E25-34A344AFD5F1 Q27022216-B5CC5F54-9CDF-460B-8FAA-17A1F1943CE0 Q27030828-8AB2A152-DABA-497C-B3F0-D9D180AB365B Q28066476-9EE8D375-A183-4283-AF03-A7DD3F812E88 Q28079550-96300BE3-8E0D-4805-AE1C-5BD0D2A134B3 Q28084820-DF5B5C1A-2CFC-44C8-B87E-37AC9749B447 Q30391932-0C33B6AA-9A25-4B16-B777-5EEFF44E19C6 Q31031231-97BE27BE-4EBA-4FC1-B9F9-FEA8312DE5CC Q33242705-9CD73CBF-A682-435E-A996-109149F98005 Q33365990-697578F4-72E2-4D91-97A3-B876224C9373 Q33439601-4CA042EF-21CF-46D4-A86D-1EFB86715B11 Q33574740-BC096118-45FB-4AA0-8149-E83F4ECB55D2 Q33592755-46FD9736-E621-41CD-A35B-DADD204DA2F3 Q33594925-43DFBC3E-5B8F-46BC-9F52-F74B33492632 Q33653027-A91F8AA5-1C43-47D6-87C6-0B04DD1F48FC Q33660010-1D463751-C967-4311-B84F-FF93E7FB84FC Q33753902-0DE36B71-BDC2-48A3-A601-D98962C60289 Q33780105-00C94E22-D5CF-4408-B15F-82582F810408 Q33787531-7A1E1436-E4F5-4F63-AD1A-E1728AA86834 Q33819124-9DCDC734-07E3-4C4C-AFAD-89F46131A534 Q33821878-93B3D9BF-BACE-4C8B-AD49-24F7A9B551DE Q33868880-706605FA-C6BC-4885-9369-919F7E624E1B Q33909717-8913997C-4DE6-4041-83B2-71AE3C0AB7C7

P2860

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

http://www.wikidata.org/entity/Q28301659

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Pegylated interferon alfa-2b a ...... epatitis B: a randomised trial

@ast

Pegylated interferon alfa-2b a ...... epatitis B: a randomised trial

@en

Pegylated interferon alfa-2b a ...... epatitis B: a randomised trial

@nl

type

label

Pegylated interferon alfa-2b a ...... epatitis B: a randomised trial

@ast

Pegylated interferon alfa-2b a ...... epatitis B: a randomised trial

@en

Pegylated interferon alfa-2b a ...... epatitis B: a randomised trial

@nl

prefLabel

Pegylated interferon alfa-2b a ...... epatitis B: a randomised trial

@ast

Pegylated interferon alfa-2b a ...... epatitis B: a randomised trial

@en

Pegylated interferon alfa-2b a ...... epatitis B: a randomised trial

@nl

P1433

Q28301659-D1A66CD2-9263-4345-9FB4-C5A998779008

P1476

Q28301659-D8084F36-28D7-4FD1-ABAC-A3C8E3B517A6

P2093

Q28301659-22EB0164-0AAC-48EC-9AC6-C99B0A026B13

Q28301659-409374B9-51FB-4E94-893E-1C0A68CD9B54

Q28301659-4BAAE5A0-CB67-4F0F-8E8B-AD4953F62E62

Q28301659-6994DFFA-B211-4B1B-A3D3-65289376146F

Q28301659-6AE06444-5C80-4435-81D2-8453F49BEC4F

Q28301659-781E8465-690B-495F-AED2-D298C7B083B6

Q28301659-A1ED883D-3ED1-46EB-B674-43FC4B508E0C

Q28301659-A35E0741-44CB-4F60-B8E6-B3481F3FC9AD

Q28301659-C2C53E24-564C-41F5-8870-2AD42EA5E4F3

Q28301659-CD684C2F-ADDC-47AC-BE69-C285D693CBDE

P304

Q28301659-95DAAC16-258C-47F5-B903-DF31845A123F

P31

Q28301659-52F0D7DC-2F71-427C-B795-F9B4F17015DF

P3181

Q28301659-DF6CD371-C6F3-47F0-A351-D5268253F669

P356

Q28301659-D867B8D4-2490-43C6-ABBA-4C98065488CF

P407

Q28301659-C28AA1A5-A5E2-4CED-8131-229CDAA82AD9

P433

Q28301659-F1D938D9-0054-417B-8C63-5A20DA12F110

P478

Q28301659-86F9CD73-B481-4889-9C92-6FA13368E59F

P50

Q28301659-081ED57D-FBF7-464E-996F-88E96A50FA50

Q28301659-3476ACBC-3DFF-43BD-B0C4-1A5A8A027B0C

Q28301659-98B4E653-8015-4272-9F68-11592F2AE343

Q28301659-EBD576E8-7CBF-4D7C-8B60-F2CBB1285427

P577

Q28301659-69F2129E-27C9-4AC9-9CAE-A7E178D0451A

P698

Q28301659-1362FA02-B576-4F3F-A0E2-74E0299C6064

P3181

P356

S0140-6736(05)17701-0

P1433

P1476

Pegylated interferon alfa-2b a ...... epatitis B: a randomised trial

@en

P2093

Christopher Simon

http://www.w3.org/2001/XMLSchema#string

Hakan Senturk

http://www.w3.org/2001/XMLSchema#string

Harry L A Janssen

http://www.w3.org/2001/XMLSchema#string

Hubert G M Niesters

http://www.w3.org/2001/XMLSchema#string

Monika van Zonneveld

http://www.w3.org/2001/XMLSchema#string

Pieter Zondervan

http://www.w3.org/2001/XMLSchema#string

Robert A de Man

http://www.w3.org/2001/XMLSchema#string

Solko W Schalm

http://www.w3.org/2001/XMLSchema#string

Thomas M K So

http://www.w3.org/2001/XMLSchema#string

Ulus S Akarca

http://www.w3.org/2001/XMLSchema#string

P304

123-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

125659

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/S0140-6736(05)17701-0

http://www.w3.org/2001/XMLSchema#string

P407

P433

9454

http://www.w3.org/2001/XMLSchema#string

P478

365

http://www.w3.org/2001/XMLSchema#string

P50

Yilmaz Cakaloglu

P577

2005-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15639293

http://www.w3.org/2001/XMLSchema#string